-transparent.png){kind=logo}
The relation between use of oral contraceptives (OCs) by young women and their risk of breast cancer before 45 years of age was investigated by analysis of data from a population-based, case-control study conducted in eight geographic regions of the United States. 2088 women with breast cancer diagnosed between Dec 1, 1980, and Dec 31, 1982, were compared with 2065 controls selected during the same period. There was no significant increase or decrease in the risk of breast cancer for OC users according to age at first use or subsequent duration of use, even for women who first used OCs before the age of 20 years and who continued to use them for more than 4 years. Risk was not altered significantly for women who used OCs with high progestagen "potency" before the age of 25 years (even when duration of use exceeded 6 years), for those who used OCs before first-term pregnancy (even when duration of use exceeded 4 years), or for OC users according to age at diagnosis. These results suggest that use of OCs by young women in the United States has no effect on the aggregate risk of breast cancer before 45 years of age.
B V Stadel, and
G L Rubin, and
L A Webster, and
J J Schlesselman, and
P A Wingo
July 1998,
Breast cancer research and treatment,
B V Stadel, and
G L Rubin, and
L A Webster, and
J J Schlesselman, and
P A Wingo
April 1985,
Cancer,
B V Stadel, and
G L Rubin, and
L A Webster, and
J J Schlesselman, and
P A Wingo
January 1986,
Acta obstetricia et gynecologica Scandinavica. Supplement,
B V Stadel, and
G L Rubin, and
L A Webster, and
J J Schlesselman, and
P A Wingo
September 1988,
Contraception,
B V Stadel, and
G L Rubin, and
L A Webster, and
J J Schlesselman, and
P A Wingo
January 1992,
Cancer causes & control : CCC,
B V Stadel, and
G L Rubin, and
L A Webster, and
J J Schlesselman, and
P A Wingo
January 2003,
British journal of cancer,
B V Stadel, and
G L Rubin, and
L A Webster, and
J J Schlesselman, and
P A Wingo
May 2014,
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
B V Stadel, and
G L Rubin, and
L A Webster, and
J J Schlesselman, and
P A Wingo
April 1989,
Journal of clinical pathology,
B V Stadel, and
G L Rubin, and
L A Webster, and
J J Schlesselman, and
P A Wingo
June 1995,
Journal of the National Cancer Institute,
B V Stadel, and
G L Rubin, and
L A Webster, and
J J Schlesselman, and
P A Wingo
September 1994,
Lancet (London, England),
